A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up

Table 3

Comparison of blood fluctuation, oxidative stress, and inflammatory profile between the dulaglutide and glimepiride groups.

	Baseline		26 weeks after treatment		Δ
	Dulaglutide	Glimepiride	Dulaglutide	Glimepiride	Dulaglutide	Glimepiride
FBG (mmol/L)
HbA1c (%)
Body weight (kg)					0.5 (-1.75, 1.25)	1.75 (-1.75, 4.12)
MBG (mmol/L)
SDBG (mmol/L)
MAGE (mmol/L)
MODD (mmol/L)
(mmol/L)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
(mmol/L)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
PT in 2.8-10 (mmol/L)	36 (4, 59.5)	16 (7.25, 57.5)	72 (47, 89)	77.5 (64.25, 89.75)	35 (25.5, 54)	51 (9.25, 75)
PT in 3.9-10 (mmol/L)	36 (4, 59.5)	16 (7.25, 57.5)	71 (41.5, 79)	77.5 (64.25, 88.25)	33 (1.5, 51.5)	49 (9.25, 75)
(mmol/L)	64 (40.5, 96)	84 (42.5, 92.75)	28 (8, 53)	22.5 (10.25, 35.75)	-35 (-54.5, -25.5)	-51 (-75, -9.25)
(mmol/L)	27 (2.5, 63)	16.5 (0.75, 37.5)	5 (0, 10.5)	0 (0, 8.75)	-20 (-52, -2)	-7.5 (-36.5, 0)
TNF-α (pg/mL)
IL-6 (pg/mL)
8-iso-PGF2α (pg/mL)

Abbreviations: FBG: fasting blood glucose; HbA1c: glycosylated hemoglobin; MBG: Mean Blood Glucose; SDBG: Standard Deviation of Blood Glucose; MAGE: Mean Amplitude of Glycemic Excursion; MODD: Absolute Means of Daily Difference; PT: percentage time; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; 8-iso-PGF2α: 8-iso-prostaglandin F2α. Data shown as or median (first quartile and third quartile).